Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25400656 | 0.94 | ADAM17 (0.38) | ADAM17ALDH1A1 | |
| SCHEMBL25398297 | 0.92 | KDM4E (0.41) | NPC1RAB9AKDM4EALDH1A1CHRM3 | |
| SCHEMBL25402654 | 0.90 | EGLN1 (0.41) | ADAM17NPC1RAB9ACHRM3GRIN2B | |
| SCHEMBL25401089 | 0.90 | GRIN2B (0.43) | NPC1RAB9AKDM4EALDH1A1GRIN2B | |
| SCHEMBL29845947 | 0.86 | GRIN2B (0.42) | ALDH1A1GRIN2BEGLN1 | |
| SCHEMBL25397996 | 0.86 | GRIN2B (0.42) | ALDH1A1GRIN2BEGLN1 | |
| SCHEMBL25399531 | 0.85 | EGLN1 (0.40) | ALDH1A1CHRM3GRIN2BTDP1L3MBTL1 | |
| SCHEMBL25400660 | 0.84 | NR4A2 (0.36) | MMP2GRIN2B | |
| SCHEMBL25398914 | 0.84 | EGLN1 (0.39) | ALDH1A1GRIN2BEGLN1 | |
| SCHEMBL25401115 | 0.84 | HCAR2 (0.38) | ADAM17CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | ADAM17 4639/4885NPC1 208/4885RAB9A 715/4885 |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | PSMB11, PSMB1, BACH1 | ADAM17 3074/4885NPC1 180/4885RAB9A 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.